mGluR2 positive allosteric modulators: an updated patent review (2013–2018)

References

• Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 2005;179:4–29.
   PubMed Web of Science ®Google Scholar
• Marek GJ, Kinon BJ, McKinzie DL, et al. Metabotropic glutamate 2/3 receptor agonists and positive allosteric modulators of metabotropic glutamate receptor 2 as novel agents for the treatment of schizophrenia. Targets Emerging Ther Schizophr. 2012;6:143–85.
   Google Scholar
• Riaza Bermudo-Soriano C, Pérez-Rodríguez MM, Vaquero-Lorenzo C, et al. New perspectives in glutamate and anxiety. Pharmacol Biochem Behav. 2012;100:752–774.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62:63–77.
   PubMed Web of Science ®Google Scholar
• Fell MJ, Witkin JM, Falcone JF, et al. N-(4-((2- (trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole- 4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. J Pharmacol Exp Ther. 2011;336:165–177.
   PubMed Web of Science ®Google Scholar
• Lindsley CW, Emmitte KA, Hopkins CR, et al. Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors. Chem Rev. 2016;116:6707–6741.
   PubMed Web of Science ®Google Scholar
• Helton DR, Tizzano JP, Monn JA, et al. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther. 1998;284:651–660.
   PubMed Web of Science ®Google Scholar
• Tizzano JP, Griffey KI, Schoepp DD. The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam. Pharmacol Biochem Behav. 2002;73:367–374.
   PubMed Web of Science ®Google Scholar
• Swanson CJ, Bures M, Johson MP, et al. Glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov. 2005;4:131–144.
   PubMed Web of Science ®Google Scholar
• Rorick-Kehn LM, Johnson BG, Knitowski KM, et al. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl). 2007;193:121–136.
   PubMed Web of Science ®Google Scholar
• Grillon C, Cordova J, Levine LR, et al. 3rd. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fearpotentiated startle paradigm in humans. Psychopharmacology (Berl). 2003;168: 446–454.
   PubMed Web of Science ®Google Scholar
• Michelson D, Levine LR, Dellva MA, et al. Clinical studies with mGlu2/3 receptor agonists: LY354740 compared with placebo in patients with generalized anxiety disorder. Neuropharmacology. 2005;49(Suppl 1):257.
   Google Scholar
• Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13:1102–1107.
   PubMed Web of Science ®Google Scholar
• Mezler M, Geneste H, Gault L, et al. LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Invest Drugs. 2010;11:833–845.
   PubMedGoogle Scholar
• Kinon BJ, Zhang L, Millen BA, et al. HBBI Study Group. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011;31:349–355.
   PubMed Web of Science ®Google Scholar
• Lilly Stops Phase III Development of Pomaglumetad Methionil for the Treatment of Schizophrenia Based on Efficacy Results ( Press Release). Eli Lilly and Company, [Aug 29, 2012; cited 2019 Apr 7]. Available from https://investor.lilly.com/news-releases/news-release-details/lilly-stops-phase-iii-development-pomaglumetad-methionil
   Google Scholar
• Woolley ML, Pemberton DJ, Bate S, et al. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl). 2008;196:431–440.
   PubMed Web of Science ®Google Scholar
• Fell MJ, Svensson KA, Johnson BG, et al. Evidence for the role of mGlu2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039. J Pharmacol Exp Ther. 2008;326:209–217.
   PubMed Web of Science ®Google Scholar
• Iacovelli L, Molinaro G, Battaglia G. Regulation of group II metabotropic glutamate receptors by G protein-coupled receptor kinases: mGlu2 receptors are resistant to homologous desensitization. Mol Pharmacol. 2009;75:991–1003.
   PubMed Web of Science ®Google Scholar
• Lennon SM, Rivero G, Matharu A, et al. Metabotropic glutamate receptor mGlu2 is resistant to homologous agonist-induced desensitization but undergoes protein kinase C-mediated heterologous desensitization. Eur J Pharmacol. 2010;649:29–37.
   PubMed Web of Science ®Google Scholar
• Urwyler S. Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives. Pharmacol Rev. 2011;63:59–126.
   PubMed Web of Science ®Google Scholar
• Pin JP, Parmentier M-L PL. Positive allosteric modulators for γ-aminobutyric acidB receptors open new routes for the development of drugs targeting family 3 G-protein-coupled receptors. Mol Pharmacol. 2001;60:881–884.
   PubMed Web of Science ®Google Scholar
• Gjoni T, Urwyler S. Receptor activation involving positive allosteric modulation, unlike full agonism, does not result in GABAB receptor desensitization. Neuropharmacology. 2008;551293–551299.
   Web of Science ®Google Scholar
• Rowe BA, Schaffhauser H, Morales S, et al. Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3 positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2 positive allosteric modulation site. J Pharmacol Exp Ther. 2008;326:240–251.
   PubMed Web of Science ®Google Scholar
• Johnson MP, Baez M, Jagdmann GE, et al. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3ylmethylamine. J Med Chem. 2003;46:3189–3192.
   PubMed Web of Science ®Google Scholar
• Levine L, Gaydos B, Sheehan D, et al. The mGlu2/3 receptor agonist, LY354740, reduces panic anxiety induced by a CO2 challenge in patients diagnosed with panic disorder. Neuropharmacology. 2002;43:294.
   Web of Science ®Google Scholar
• Fell MJ, McKinzie DL, Monn JA, et al. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology. 2012;62:1473–1483.
   PubMed Web of Science ®Google Scholar
• Rodriguez D, Bonnefous C, Kamenecka T, et al. Attenuation of ketamine-induced hyperactivity responses in rats following administration of a novel metabotropic glutamate receptor 2 selective positive modulator [abstract]. Proceedings of the Annual Meeting of the Society for Neuroscience; 2004 Oct 23–27; Abstract number 798.8, Dallas, TX. Washington, DC: Society for Neuroscience.
   Google Scholar
• Galici R, Jones CK, Hemstapat K, et al. Biphenyl-Indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther. 2006;318:173–185.
   PubMed Web of Science ®Google Scholar
• Sheffler DJ, Pinkerton AB, Dahl R, et al. Recent progress in the synthesis and characterization of group II metabotropic glutamate receptor allosteric modulators. ACS Chem Neurosci. 2011;2:382–393.
   PubMed Web of Science ®Google Scholar
• Rudd MT, McCauley JA. Positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (mGluR2). Curr Top Med Chem. 2005;5:869–884.
   PubMed Web of Science ®Google Scholar
• Fraley ME. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Patents. 2009;19:1259–1275.
   PubMed Web of Science ®Google Scholar
• Trabanco AA, Cid JM, Lavreysen H, et al. Progress in the development of positive allosteric modulators of the metabotropic glutamate receptor 2. Curr Med Chem. 2011;18:47–68.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov (2009) Study to assess the efficacy, safety, and tolerability of ADZ8529 in adult schizophrenia patients. http://clinicaltrials.gov/show/NCT00921804; accessed July 1st, 2019
   Google Scholar
• The effects ADZ8529 on cognition and negative symptoms in schizophrenics. 2009. http://clinicaltrials.gov/show/NCT00986531; accessed July 1st, 2019
   Google Scholar
• Litman RE AZD8529, A positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: a proof of principle study NCDEU An Annual Meeting of the ASCP Westin Diplomat; 2013 May 28–31; Hollywood Florida, US
   Google Scholar
• Litman RE, Smith MA, Doherty JJ, et al. AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Schizophr Res. 2016;172:152–157.
   PubMed Web of Science ®Google Scholar
• Cook D, Brown B, Alexander R, et al. Nat Rev Drug Discovery. 2014;13:419–431.
   PubMed Web of Science ®Google Scholar
• Justinova Z, Panlilio LV, Secci ME, et al. The novel metabotropic glutamate receptor 2 positive allosteric modulator, AZD8529, decreases nicotine self-administration and relapse in squirrel monkeys. Biol Psychiatry. 2015;78:452–462.
   PubMed Web of Science ®Google Scholar
• Acri JB, Cross AJ, Skolnick P. From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders. Psychopharmacology (Berl). 2017;234:1347–1355.
   PubMed Web of Science ®Google Scholar
• Lavreysen H Discovery and early clinical development of novel mGlu2 receptor PAMs. American College of Neuropsychopharmacology (ACNP) 52nd Annual Meeting; 2013 Dec 10; Hollywood, Florida, US
   Google Scholar
• Study to explore the safety, tolerability and potential clinical efficacy of JNJ-40411813 in schizophrenic patients. 2011. http://clinicaltrials.gov/show/NCT01323205; accessed July 1st, 2019
   Google Scholar
• Kent JM, Daly E, Kezic I, et al. Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression. Prog Neuropsychopharmacol Biol Psychiatry. 2016;67:66–73.
   PubMed Web of Science ®Google Scholar
• Cameron S, Metcalf BD, Klein MD, et al. Efficacy of mGlu2-positive allosteric modulators alone and in combination with levetiracetam in the mouse 6 Hz model of psychomotor seizures. Epilepsia. 2017;58:484–493.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica NV. 2015. Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use . (WO110435).
   Google Scholar
• Metcalf BD, Klein MD, Smith MD, et al. Potent and selective pharmacodynamic synergy between the metabotropic glutamate receptor subtype 2-positive allosteric modulator JNJ-46356479 and levetiracetam in the mouse 6-Hz (44-mA) model. Epilepsia. 2018;59:725–735.
   Web of Science ®Google Scholar
• Fraley ME. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Patents. 2009;19:1259–1275.
   PubMed Web of Science ®Google Scholar
• Trabanco AA, Cid JM. mGluR2 positive allosteric modulators (PAMs): a patent review (2009 - present). Expert Opin Ther Patents. 2013;23:629–647.
   PubMed Web of Science ®Google Scholar
• AstraZeneca AB and NPS Pharmaceuticals Inc. 2006. Isoindolone compounds and their use as metabotropic glutamate receptor potentiators. (WO020879).
   Google Scholar
• AstraZeneca AB. 2017. Deuterated isoxazole derivatives and their use as metabotropic glutamate receptor potentiators. (US0145002).
   Google Scholar
• AstraZeneca AB preparation of isoxazole derivatives and their use as metabotropic glutamate receptor potentiators. 2009. (WO148403).
   Google Scholar
• Bristol-Myers Squibb Company. Positive allosteric modulators of mGluR2. 2013. (WO138687).
   Google Scholar
• Bristol-Myers Squibb Company. 2013. Positive allosteric modulators of mGluR2. (WO192306).
   Google Scholar
• Bristol-Myers Squibb Company. 2015. Positive allosteric modulators of mGluR2. (WO042243).
   Google Scholar
• Higgis MA, Marcin LR, Zusi FC, et al. Triazolopyridine ethers as potent, orally active mGlu2 positive allosteric modulators for treating schizophrenia. Biorg Med Chem. 2017;25:496–513.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica NV 1,2,4-Triazolopyridine[4,3-a]pyridine compounds and their use as positive allosteric modulators of mGlu2 receptors. 2015. (WO032790).
   Google Scholar
• Janssen Pharmaceutica NV 1,2,4-Triazolopyridine[4,3-a]pyridine compounds and their use as positive allosteric modulators of mGlu2 receptors. 2015. (WO092002).
   Google Scholar
• Barton ME, Klein BD, Wolf HH, et al. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001;47:217–222.
   PubMed Web of Science ®Google Scholar
• Sandford-Burnham Medical Research Institute. Metabotropic glutamate receptor positive allosteric modulators (PAMs) and uses thereof. 2015. (WO157187).
   Google Scholar
• Pinkerton AB, Vernier J-M, Schaffhauser H, et al. Phenyl-tetrazolyl acetophenones: discovery of allosteric potentiators for the metabotropic glutamate 2 receptor. J Med Chem. 2004;47:4595–4599.
   PubMed Web of Science ®Google Scholar
• Pinkerton AB, Cube RV, Hutchinson JH, et al. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 1: identification and synthesis of phenyl-tetrazolyl acetophenones. Bioorg Med Chem Lett. 2004;14:5329–5332.
   PubMed Web of Science ®Google Scholar
• Cube RV, Vernier J-M, Hutchinson JH, et al. 3-(2-ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}phenylpropanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2). Bioorg Med Chem Lett. 2005;15:2389–2393.
   PubMed Web of Science ®Google Scholar
• Bonnefous C, Vernier J-M, Hutchinson JH, et al. Biphenyl-indanones: allosteric potentiators of metabotropic glutamate subtype 2 receptor. Bioorg Med Chem Lett. 2005;15:4354–4358.
   PubMed Web of Science ®Google Scholar
• Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Fluorine-containing triazolopyridine, and manufacturing method, pharmaceutical composition, and application thereof. 2017. (CN107383002)
   Google Scholar
• Shanghai Institute of Materia Medica, Chinese Academy of Sciences. 2017. Fluorine-containing triazolopyridine, and manufacturing method, pharmaceutical composition, and application thereof. (WO198180).
   Google Scholar
• Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Addex Pharma S.A. 7-Aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors. 2010. (WO130423).
   Google Scholar
• Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Addex Pharma S.A. 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders. 2010. (WO130424).
   Google Scholar
• Pharma SD. Dihydroimidazopyrazinone derivatives. 2013. (JP166727).
   Google Scholar
• Pharma SD. Dihydropyrrolopyrazinone derivatives. 2013. (JP189395).
   Google Scholar
• Taisho Pharmaceutical CO., LTD. Imidazolone derivatives. WO062074 (2013).
   Google Scholar
• Taisho Pharmaceutical CO., LTD. Imidazolone derivatives. 2015. (JP6993).
   Google Scholar
• Taisho Pharmaceutical CO., LTD. Imidazoimidazolone derivatives. 2014. (JP214124).
   Google Scholar
• Sanofi-Aventis. Substituted dihydro and tetrahydro oxazolopyrimidones, preparation and use thereof. 2008. (WO112483)
   Google Scholar
• Sanofi-Aventis. Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidones, preparation and use thereof as allosteric modulators of mGluR. 2009. (WO110901).
   Google Scholar
• Sanofi-Aventis. Substituted para-biphenyloxymethyl dihydro oxazolopyrimidones, preparation and use thereof. 2011. WO034828).
   Google Scholar
• Sanofi-Aventis. Substituted benzocycloalkyloxymethyl oxazolopyrimidones, preparation and use thereof. 2011. (WO034830)
   Google Scholar
• Sanofi-Aventis. Substituted phenoxymethyl dihydro oxazolopyrimidones, preparation and use thereof. 2011. (WO034832)
   Google Scholar
• Merck & Co., Inc., Oxazolobenzimidazolone derivatives. 2009. (WO140163)
   Google Scholar
• Merck & Co., Inc., Oxazolobenzimidazolone derivatives. 2009. (WO140166)
   Google Scholar
• Garbaccio RM, Brnardic EJ, Fraley ME, et al. Discovery of oxazolobenzimidazoles as positive allosteric modulators for the mGluR2 receptor. ACS Med Chem Lett. 2010;1:406–410.
   PubMed Web of Science ®Google Scholar
• Taisho Pharmaceutical CO., LTD. Dihydroimidazooxazole derivative. 2013. (WO062079).
   Google Scholar
• Taisho Pharmaceutical CO., LTD. Medicine containing a dihydroimidazooxazole derivative. 2014. (JP214130)
   Google Scholar
• Taisho Pharmaceutical CO., LTD. Dihydroimidazooxazole derivatives. 2015. (JP006994)
   Google Scholar
• Hiyoshi T, Marumo T, Hikichi H, et al. Neurophysiologic and antipsychotic profiles of TASP0433864 a novel positive allosteric modulator of metabotropic glutamate 2 receptor. J Pharmacol Exp Ther. 2014;351:642–653.
   PubMed Web of Science ®Google Scholar